Novartis skin cancer drug meets endpoint in trial

Share this article:

Novartis announced today that investigational oral medicine LDE225, for advanced basal cell carcinoma hit, what the drugmaker calls "objective response," or showed a clinically significant tumor response (absence of disease) or a partial response (tumor shrinkage) after six months of treatment in Phase-II trials.

Novartis's head of oncology, Alessandro Riva, stated, "for people living with advanced basal cell carcinoma there are currently limited treatment options," adding, "these results demonstrate the potential for LDE225 to offer a treatment option for this patient population, and we look forward to sharing these data with regulatory authorities worldwide."

Basal cell carcinoma is the most common form of skin cancer, according to the Skin Care Foundation. Novartis has plans to file LDE225 in 2014.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.